Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first financial year as an independent company. After completing its spin-off from ...

Alvotech, a biotech firm focused on biosimilar ... looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example ...

AVT03 is a human monoclonal antibody and biosimilar ... statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example ...

In the American drug industry, a trend has developed among manufacturers and pharmacy benefits managers (PBM) that threatens to upend a productive balance between rewarding manufacturer innovation ...

For example, in 2015, an Indian manufacturer of a biosimilar for Razumab, used to treat macular degeneration, had to recall the biosimilar from the market after doctors prescribing the drug ...

2 “For patients with chronic inflammatory diseases requiring long-term treatment, especially those who are currently well-managed, the idea of switching to a different biosimilar can be a ...

J&J (NYSE:JNJ) said in a statement to Seeking Alpha on Tuesday that the company has an agreement with Samsung Bioepis that allows for a biosimilar of Stelara to be launched before its patent ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number of FDA-approved biosimilars to 63. Forty-one of those biosimilars have ...

Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech’s expectations regarding competitive ...

For Europe, it is still too early to model,” Sandoz CEO Richard Saynor said in a statement to Pharmaceutical Technology. Sandoz pointed to the uptake of its Humira biosimilar Hyrimoz in the US ...